CytoDyn’s (CYDY) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of CytoDyn (OTCMKTS:CYDY) in a research note published on Friday.

Separately, ValuEngine raised CytoDyn from a strong sell rating to a sell rating in a report on Thursday, September 7th.

Shares of CytoDyn (CYDY) traded down $0.03 on Friday, reaching $0.57. The company had a trading volume of 140,648 shares, compared to its average volume of 132,015. CytoDyn has a 52 week low of $0.46 and a 52 week high of $0.84.

CytoDyn (OTCMKTS:CYDY) last announced its quarterly earnings data on Tuesday, October 10th. The biotechnology company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.03). analysts forecast that CytoDyn will post -0.19 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “CytoDyn’s (CYDY) “Buy” Rating Reaffirmed at HC Wainwright” was published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at

About CytoDyn

CytoDyn Inc is a clinical-stage biotechnology company. The Company is focused on the clinical development and commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The Company’s lead product candidate, PRO 140, belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells.

Receive News & Ratings for CytoDyn Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply